Begin main content

Reports

We found 5888 result(s)

siponimod (Mayzent)

Last Updated: February 19, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: siponimod
Indications: Secondary progressive multiple sclerosis

  • Brand Name: Mayzent
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0631-000
  • Project Status: Active
  • Submission Type: New

brolucizumab (TBC)

Last Updated: February 20, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: brolucizumab
Indications: Macular degeneration, age-related

  • Brand Name: TBC
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: SR0632-000
  • Project Status: Active
  • Submission Type: New

vedolizumab (Entyvio )

Last Updated: February 19, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: vedolizumab
Indications: Ulcerative Colitis

  • Brand Name: Entyvio
  • Manufacturer: Takeda Canada Inc.
  • Project Number: SR0635-000
  • Project Status: Active
  • Submission Type: New

vortioxetine hydrobromide (Trintellix )

Last Updated: February 20, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: vortioxetine hydrobromide
Indications: Major depressive disorder (MDD), adults.

  • Brand Name: Trintellix
  • Manufacturer: Lundbeck Canada Inc.
  • Project Number: SR0611-000
  • Project Status: Active
  • Submission Type: New

glucagon (Baqsimi)

Last Updated: February 20, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: glucagon
Indications: Severe hypoglycemic reactions

  • Brand Name: Baqsimi
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0626-000
  • Project Status: Active
  • Submission Type: New

sodium zirconium cyclosilicate (Lokelma)

Last Updated: February 3, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: sodium zirconium cyclosilicate
Indications: Hyperkalemia, adults

  • Brand Name: Lokelma
  • Manufacturer: AstraZeneca Canada Inc.
  • Project Number: SR0612-000
  • Project Status: Active
  • Submission Type: New

tafamidis (Vyndaqel)

Last Updated: February 21, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: tafamidis
Indications: transthyretin-mediated amyloidosis

  • Brand Name: Vyndaqel
  • Manufacturer: Pfizer Canada
  • Project Number: SR0625-000
  • Project Status: Active
  • Submission Type: New

etonogestrel (TBC)

Last Updated: February 20, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: etonogestrel
Indications: Prevention of pregnancy

  • Brand Name: TBC
  • Manufacturer: Merck Canada Inc.
  • Project Number: SR0629-000
  • Project Status: Withdrawn
  • Submission Type: New

caplacizumab (Cablivi)

Last Updated: February 19, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: caplacizumab
Indications: Acquired thrombotic thrombocytopenic purpura (aTTP)

  • Brand Name: Cablivi
  • Manufacturer: Sanofi-Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0633-000
  • Project Status: Active
  • Submission Type: New

ixekizumab (Taltz )

Last Updated: February 19, 2020
Result type: Reports
Product Line: Common Drug Review
Generic Name: ixekizumab
Indications: Ankylosing spondylitis

  • Brand Name: Taltz
  • Manufacturer: Eli Lilly Canada Inc.
  • Project Number: SR0630-000
  • Project Status: Active
  • Submission Type: New Indication